Loading…
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-326M | $-303M | $-249M | -34.5% | -100.0% | - |
| 2024 | $9M | $-200M | $-183M | $-132M | -41.0% | 249.5% | - |
| 2023 | $2M | $-126M | $-123M | $-111M | -176.9% | - | - |
| 2022 | $0M | $-215M | $-214M | $-185M | -281.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 2.45 | 8.55 | 0 |
| Operating Expense | 214.99 | 128.82 | 208.72 | 326.20 |
| Operating Income | -214.99 | -126.37 | -200.16 | -326.20 |
| EBITDA | -214.57 | -125.94 | -199.81 | -326.06 |
| EBIT | -214.99 | -126.37 | -200.16 | -326.20 |
| Pretax Income | -214.03 | -123.28 | -182.82 | -303.27 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -214.03 | -123.28 | -182.82 | -303.27 |
| Net Income Common Stockholders | -214.03 | -123.28 | -182.82 | -303.27 |
| Total Expenses | 214.99 | 128.82 | 208.72 | 326.20 |
| Research And Development | 155.04 | 86.77 | 152.41 | 267.12 |
| Selling General And Administration | 59.95 | 42.05 | 56.30 | 59.08 |
| Normalized EBITDA | -214.57 | -125.94 | -199.81 | -326.06 |
| Normalized Income | -214.03 | -123.28 | -182.82 | -303.27 |
| Basic EPS | -69.60 | -18.69 | -10.21 | 0 |
| Diluted EPS | -69.60 | -18.69 | -10.21 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -214.03 | -123.28 | -182.82 | -303.27 |
| Reconciled Depreciation | 0.42 | 0.43 | 0.36 | 0.14 |
| Net Income From Continuing And Discontinued Operation | -214.03 | -123.28 | -182.82 | -303.27 |
| Total Operating Income As Reported | -214.99 | -126.37 | -200.16 | -326.20 |
| Diluted Average Shares | 3.07 | 6.59 | 17.91 | 0 |
| Basic Average Shares | 3.07 | 6.59 | 17.91 | 0 |
| Diluted NI Availto Com Stockholders | -214.03 | -123.28 | -182.82 | -303.27 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -214.03 | -123.28 | -182.82 | -303.27 |
| Net Income Continuous Operations | -214.03 | -123.28 | -182.82 | -303.27 |
| Other Income Expense | 0.96 | 3.10 | 17.35 | 22.93 |
| Other Non Operating Income Expenses | 0.96 | 3.10 | 17.35 | 22.93 |
| General And Administrative Expense | 59.95 | 42.05 | 56.30 | 59.08 |
| Other Gand A | 59.95 | 42.05 | 56.30 | 59.08 |
| Operating Revenue | 0 | 2.45 | 8.55 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines, Inc.this co. | PRAX | $9.0B | - | 9.27 | -34.5% | -25.77 |
| Guardant Health, Inc. | GH | $11.1B | - | -109.75 | 419.2% | -28.87 |
| The Ensign Group, Inc. | ENSG | $10.9B | 31.92 | 4.82 | 15.4% | 23.43 |
| Axsome Therapeutics, Inc. | AXSM | $9.5B | - | 106.02 | -207.5% | -58.09 |
| Vaxcyte, Inc. | PCVX | $8.3B |
| - |
| 2.80 |
| -28.5% |
| -7.50 |
| Nuvalent, Inc. | NUVL | $7.8B | - | 6.21 | -34.1% | - |
| Cytokinetics, Incorporated | CYTK | $7.4B | - | -11.11 | 119.0% | -13.11 |
| Apogee Therapeutics, Inc. | APGE | $7.3B | - | 6.21 | -28.3% | -17.34 |
| ImmunityBio, Inc. | IBRX | $7.2B | - | -14.06 | 70.3% | -32.25 |
| Peer Median | - | 31.92 | 3.81 | -6.5% | -17.34 | |